Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.
Stocks · News reference
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term
The Vanguard S&P 500 Growth ETF (VOOG) tracks the S&P 500 Growth index of 151 best-performing growth stocks, heavily weighted toward AI and technology companies. With a 16.9% compound annual return since 2010 and 28.4% over the last three years, consistent $500 monthly investments could potentially reach $1 million in approximately 23 years, even at conservative 14.1% annual returns.